US 11214801
RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
granted A61KA61K9/0019A61P
Quick answer
US patent 11214801 (RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)) held by Arrowhead Pharmaceuticals, Inc. expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Arrowhead Pharmaceuticals, Inc.
- Grant date
- Tue Jan 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 30
- CPC classes
- A61K, A61K9/0019, A61P, A61P1/18, A61P3/04